![Eric Poma](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Poma
Chief Executive Officer at
MOLECULAR TEMPLATES, INC.
Net worth: 4 250 $ as of 30/06/2026
Profile
Dr. Eric E.
Poma is a Chairman & Chief Executive Officer at Calidi Biotherapeutics (Nevada), Inc., a Chief Executive Officer & Director at Calidi Biotherapeutics, Inc., a Chief Executive Officer & Director at Molecular Templates, Inc. and a Chief Executive Officer & Director at Molecular Templates OpCo, Inc. He is on the Board of Directors at Calidi Biotherapeutics, Inc., Molecular Templates, Inc. and Molecular Templates OpCo, Inc. Dr. Poma was previously employed as a Vice President-Business Development by Innovive Pharmaceuticals, Inc. and an Assistant Vice President-Business Development by ImClone LLC.
He received his undergraduate degree from the University of North Carolina at Chapel Hill, an MBA from The Leonard N Stern School of Business and a doctorate degree from the University of North Carolina at Chapel Hill.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 17/04/2026 | 25,000 ( 0.7% ) | 4 250 $ | 30/06/2026 |
Eric Poma active positions
| Companies | Position | Start |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Chief Executive Officer | 01/01/2000 |
| CALIDI BIOTHERAPEUTICS, INC. | Chief Executive Officer | 22/04/2025 |
Molecular Templates OpCo, Inc.
 Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Functions as an investment holding company | Chief Executive Officer | - |
Calidi Biotherapeutics, Inc. (United States)
 Calidi Biotherapeutics, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage immuno-oncology company | Chief Executive Officer | 22/04/2025 |
Former positions of Eric Poma
| Companies | Position | End |
|---|---|---|
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Corporate Officer/Principal | - |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Corporate Officer/Principal | - |
Training of Eric Poma
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
15
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Templates, Inc.
 Molecular Templates, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company | Commercial Services |
Calidi Biotherapeutics, Inc. (United States)
Calidi Biotherapeutics, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage immuno-oncology company | Commercial Services |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Calidi Biotherapeutics, Inc.
 Calidi Biotherapeutics, Inc. BiotechnologyHealth Technology Develops immunotherapies which attacks solid tumors | Health Technology |
University of North Carolina at Chapel Hill
 University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Eric Poma
